PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33403775-8	2021	In the 31 patients who received ruxolitinib symptoms improved (dyspnea scale) at day 7 in 25 out of 31 patients (80.6%); C-reactive protein decreased progressively from baseline (79.1+-73.4 mg/dl) to day15 (18.6+-33.2, p=0.022).	ruxolitinib	32-43	C-reactive protein	Homo sapiens	121-139	
26463833-3	2015	Ruxolitinib increased median survival from 1.8 to 2.7 months in patients with pancreatic cancer who had high levels of the inflammation marker C-reactive protein in their blood.	ruxolitinib	0-11	C-reactive protein	Homo sapiens	143-161	
25441108-10	2015	One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d.	ruxolitinib	75-86	C-reactive protein	Homo sapiens	66-69	
29675680-0	2018	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.	ruxolitinib	45-56	C-reactive protein	Homo sapiens	168-186	
26351344-7	2015	In a prespecified subgroup analysis of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (ie, 13 mg/L), OS was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI, 0.26 to 0.85; P = .011).	ruxolitinib	200-211	C-reactive protein	Homo sapiens	84-102	
31654094-0	2020	Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.	ruxolitinib	81-92	C-reactive protein	Homo sapiens	21-39	
31654094-0	2020	Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.	ruxolitinib	81-92	C-reactive protein	Homo sapiens	41-44	
31654094-1	2020	OBJECTIVE AND DESIGN: To determine whether inflammatory hepatocytes may constitute primary targets for ruxolitinib, a Janus kinase (JAK) inhibitor, its effects towards expression of hepatic acute-phase proteins, especially C-reactive protein (CRP), were assessed.	ruxolitinib	103-114	C-reactive protein	Homo sapiens	223-241	
31654094-3	2020	RESULTS: Ruxolitinib was found to fully inhibit lipopolysaccharide (LPS)-induced CRP secretion and mRNA expression, at concentrations (IC50 = 12.9 nM) achievable in human blood.	ruxolitinib	9-20	C-reactive protein	Homo sapiens	81-84	
31654094-5	2020	Ruxolitinib was additionally found to block the activation of the IL6/JAK/signal transducer and activator of transcription (STAT) pathway triggered by LPS and whose inhibition by the neutralizing anti-IL6 receptor antibody tocilizumab prevented CRP induction.	ruxolitinib	0-11	C-reactive protein	Homo sapiens	245-248	
31654094-6	2020	CONCLUSION: Ruxolitinib can potently repress induction of CRP in inflammatory human hepatocytes, most likely through targeting the IL6/JAK/STAT signalling cascade.	ruxolitinib	12-23	C-reactive protein	Homo sapiens	58-61	
29508247-1	2018	Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] >13 mg/dL) in the randomized phase II RECAP study.	ruxolitinib	11-22	C-reactive protein	Homo sapiens	225-243	
25441108-11	2015	CONCLUSION: In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.	ruxolitinib	103-114	C-reactive protein	Homo sapiens	179-182